Trial Profile
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms BORTEJECT
- 01 Sep 2021 Results investigating diagnostic accuracy of donor-derived cell-free DNA in cohort of DSA-positive patients, presented at the 20th Congress of the European Society for Organ Transplantation
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.